Cecil Nick

Cecil has amassed over 30 years of experience in regulatory affairs and clinical development, with a focus on biological medicines for the past 25 years. His expertise lies in monoclonals and biosimilars, spanning various therapeutic areas including oncology, inflammatory disease, diabetes, growth factors, multiple sclerosis, neurology, antivirals, blood products, and vaccines. Since joining Parexel in 2001, he has been instrumental in clinical development, regulatory submissions, biosimilars, orphan drugs, and training. He crafts efficient and effective clinical development plans, collaborating with pharmacologists, statisticians, therapeutic experts and conducting feasibility analyses.